Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.
Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX. Nicolini FE, et al. Among authors: gagnieu mc. Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7. Lancet Haematol. 2015. PMID: 26687426 Clinical Trial.
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells.
Berger MG, Lebecque B, Tassin T, Dannus LT, Berger J, Soucal M, Guerci A, Cony-Makhoul P, Johnson H, Etienne G, Guyotat D, Gagnieu MC, Pereira B, Saugues S, Tournilhac O, Hermet E, Bourgne C. Berger MG, et al. Among authors: gagnieu mc. Sci Rep. 2021 Mar 17;11(1):6187. doi: 10.1038/s41598-021-85734-0. Sci Rep. 2021. PMID: 33731863 Free PMC article.
Measurement of imatinib uptake by flow cytometry.
Bourgne C, Bamdad M, Janel A, Libert F, Gagnieu MC, Rapatel C, Pigeon P, Pereira S, Hermet E, Guerci A, Pereira B, Makhoul PC, Ansah AJ, Cahn JY, Guyotat D, Trouillier S, Berger J, Boiret-Dupré N, Berger MG. Bourgne C, et al. Among authors: gagnieu mc. Cytometry A. 2012 Nov;81(11):996-1004. doi: 10.1002/cyto.a.22118. Epub 2012 Aug 28. Cytometry A. 2012. PMID: 22930640 Free article.
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Pradat P, Durant J, Brochier C, Trabaud MA, Cottalorda-Dufayard J, Izopet J, Raffi F, Lucht F, Gagnieu MC, Gatey C, Jacomet C, Vassallo M, Dellamonica P, Cotte L; No Nuc No Boost Study Group. Pradat P, et al. Among authors: gagnieu mc. J Antimicrob Chemother. 2016 Nov;71(11):3235-3241. doi: 10.1093/jac/dkw273. Epub 2016 Jul 17. J Antimicrob Chemother. 2016. PMID: 27432606 Clinical Trial.
Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin.
Loustaud-Ratti V, Maynard M, Thevenon S, Pradat P, Rousseau A, Alain S, Deny P, Gagnieu MC, Tran A, Dao T, Silvain C, Lunel-Fabiani F, Picard N, Zublena I, Marquet P, Trepo C; RIBAJUSTE Group. Loustaud-Ratti V, et al. Among authors: gagnieu mc. Ther Drug Monit. 2016 Dec;38(6):684-692. doi: 10.1097/FTD.0000000000000332. Ther Drug Monit. 2016. PMID: 27559840 Clinical Trial.
Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy.
Pradat P, Virlogeux V, Maynard M, Leclercq M, Hatu G, Amiri M, Lebosse F, Miailhes P, Zoulim F, Gagnieu MC, Bailly F. Pradat P, et al. Among authors: gagnieu mc. Hepat Mon. 2015 Sep 1;15(9):e28879. doi: 10.5812/hepatmon.28879. eCollection 2015 Sep. Hepat Mon. 2015. PMID: 26500683 Free PMC article.
115 results